糖尿病の足の潰瘍の管理におけるGLP-1剤の役割に関する記述と体系的レビュー
Fiona S Gruzmark1, Gabriela E Beraja1, Ivan Jozic1
1Dr. Phillip Frost Department of Dermatology and Cutaneous Surgery, University of Miami Miller School of Medicine, Miami, Florida, USA.
まとめ
グルカゴン類ペプチド1受容体アゴニストは,傷の治癒を改善し,合併症を軽減することによって,糖尿病足の潰瘍の管理に潜在性を示しています. 再発を防ぐための保護作用を確認するためにさらなる研究が必要である.
科学分野:
- 内分泌学 と 代謝 疾患
- 皮膚科
- 血管 外科
背景:
- 糖尿病による足の潰瘍は 世界中で何百万もの患者を抱え 高い罹病率と死亡率をもたらしています
- 高い再発率と 切断などの合併症は 新しい治療法の必要性を強調しています
- グルカゴン類ペプチド1受容体アゴニスト (GLP- 1 RAs) は,糖尿病と体重管理のためにますます使用されています.
研究 の 目的:
- 糖尿病足の潰瘍の管理における全身性GLP-1RAの可能性を調査する.
- 傷の修復,マイクロ血管機能,炎症に対するGLP-1RAの影響を調査する.
- GLP-1 RAsを使用した患者と対照群における糖尿病足の合併症の割合を評価する.
主な方法:
- PRISMAのガイドラインに従って体系的なレビューを行う.
- 皮膚疾患におけるGLP-1RAの使用に関する既存の文献の分析
- GLP-1 RA使用者と対照群における糖尿病足の合併症の比較評価
主要な成果:
- GLP- 1 RAsは,傷の修復,マイクロ血管機能,および炎症を含む糖尿病足の潰瘍の病理学的側面を調節する可能性があります.
- 糖尿病足の合併症に対するGLP-1RAの潜在的保護作用を示唆している.
- 他の皮膚疾患からの証拠は,GLP-1 RAの使用でポジティブな結果を示しています.
結論:
- 糖尿病の足の潰瘍の治療には有望な治療法である.
- 複数の病理学的要因に対処することで,GLP-1RAは糖尿病足の潰瘍の再発を防ぐのに役立ちます.
- 糖尿病足の潰瘍に対するGLP-1RAの有効性と安全性を確立するために,さらなる臨床試験が必要である.
関連する概念動画
01:24Glucagon-like Receptor Agonists
416
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
416
01:23Dipeptidyl Peptidase 4 Inhibitors
252
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
252
01:26Peripheral Artery Disease IV: Nursing Management
43
The nursing management of a patient with peripheral artery disease (PAD) begins with a thorough assessment of the patient’s health history and clinical manifestations.AssessmentHealth History: Evaluate the patient’s history of hypertension, hyperlipidemia, family history of cardiovascular issues, and lifestyle factors such as dietary patterns, smoking, and physical activity.Physical Examination:Assess the affected extremity for decreased or absent peripheral pulses,...
43
01:06Oral Hypoglycemic Agents: Glinides
256
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
256
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
255
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
255
01:15Diabetes: Management and Pharmacotherapy
354
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
354